Platinum‐based chemotherapy plus cetuximab first‐line for Asian patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck: Results of an open‐label, single‐arm, multicenter trial-Reference-Cited by-同舟云学术

Platinum‐based chemotherapy plus cetuximab first‐line for Asian patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck: Results of an open‐label, single‐arm, multicenter trial

Published:2014-09-17 Issue:8 Volume:37 Page:1081-1087
ISSN:1043-3074
Container-title:Head & Neck
language:en
Short-container-title:Head Neck

Author:

Guo Ye¹,Shi Mei²,Yang Ankui³,Feng Jifeng⁴,Zhu Xiaodong⁵,Choi Young‐Jin⁶,Hu Guoqin⁷,Pan Jianji⁸,Hu Chunhong⁹,Luo Rongcheng¹⁰,Zhang Yiping¹¹,Zhou Liang¹²,Cheng Ying¹³,Lüpfert Christian¹⁴,Cai Junliang¹⁵,Shi yuankai¹⁶

Affiliation:

1. Medical Oncology DepartmentFudan University Shanghai Cancer CenterShanghai China

2. Radiation Oncology DepartmentXijing Hospital – The First Affiliated Hospital of the Fourth Military Medical University Shanxi Province China

3. Head and Neck DepartmentSun Yat‐sen University Cancer CenterGuangzhou China

4. Medical Oncology DepartmentJiangsu Cancer HospitalNanjing Jiangsu Province China

5. Radiotherapy DepartmentAffiliated Cancer Hospital, Guangxi Medical UniversityNanning Guangxi Province China

6. Medical Oncology DepartmentPusan National University HospitalSeo‐Gu Busan Korea

7. Cancer DepartmentTongji Hospital of Tongji Medical College of Huazhong University of Science and TechnologyWuhan China

8. Department of Radiation OncologyFujian Provincial Cancer HospitalFuzhou China

9. Oncology DepartmentThe Second Xiangya Hospital of Central South UniversityChangsha Hu'nan Province China

10. Cancer Medical DepartmentNanfang HospitalGuangzhou China

11. Chemotherapy CenterZhejiang Cancer HospitalHangzhou Zhejiang Province China

12. Head and Neck Surgery DepartmentEye and Ear, Nose, and Throat Hospital of Fudan UniversityXuhui District Shanghai China

13. Medical Oncology DepartmentJilin Cancer HospitalChangchun Jilin China

14. Merck KGaADarmstadt Germany

15. Merck Serono (Beijing) Pharmaceutical R&D CompanyThe Center Shanghai China

16. Department of Medical OncologyCancer Institute/Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing Key Laboratory of Clinical Study on Anticancer Molecular Targeted DrugsChaoyang District Beijing China

Funder

The trial was sponsored by Merck KGaA, Darmstadt, Germany

Publisher

Wiley

Subject

Otorhinolaryngology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/hed.23707

Reference25 articles.

1. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008

2. Chinese Cancer Registry Annual Report 2008: National Office for Cancer Prevention and Control and National Central Cancer Registry Disease Prevention and Control Bureau Ministry of Health;2009.

3. Optimal treatment for recurrent/metastatic head and neck cancer

4. NCCN Clinical Practice Guidelines in Oncology: Head and Neck Cancers. Version 1.2012 ed.National Comprehensive Cancer Network Inc.;2012. Available at:http://www.nccn.org. Accessed August 1 2013.

5. Squamous cell carcinoma of the head and neck: EHNS–ESMO–ESTRO Clinical Practice Guidelines for diagnosis, treatment and follow-up

Cited by 23 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. In vitro evaluation of photon and carbon ion radiotherapy in combination with cisplatin in head and neck squamous cell carcinoma cell lines;Frontiers in Oncology;2023-04-04

2. Costunolide enhances cisplatin-induced cytotoxicity in hypopharyngeal SCC FaDu cells by increasing the production of reactive oxygen species;Pathology - Research and Practice;2022-08

3. First-line treatment with chemotherapy plus cetuximab in Chinese patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck: Efficacy and safety results of the randomised, phase III CHANGE-2 trial;European Journal of Cancer;2021-10

4. Current Updates on Cancer-Causing Types of Human Papillomaviruses (HPVs) in East, Southeast, and South Asia;Cancers;2021-05-30

5. Modified TPEx as First-line Treatment for Recurrent and/or Metastatic Head and Neck Cancer;Anticancer Research;2021-04